RNAi therapeutics for CNS disorders

被引:35
|
作者
Boudreau, Ryan L. [1 ]
Davidson, Beverly L. [1 ,2 ]
机构
[1] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA
[2] Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA
关键词
RNAi; Therapy; Neurodegenerative; Huntington's; Alzheimer's; Parkinson's; Ataxias; DOUBLE-STRANDED-RNA; SMALL INTERFERING RNA; POLYGLUTAMINE-INDUCED NEURODEGENERATION; HUNTINGTONS-DISEASE; ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; PROLONGS SURVIVAL; MUTANT SOD1; TRANSGENIC MICE; GENE-EXPRESSION;
D O I
10.1016/j.brainres.2010.03.038
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
RNA interference (RNAi) is a process of sequence-specific gene silencing and serves as a powerful molecular tool to manipulate gene expression in vitro and in vivo. RNAi technologies have been applied to study gene function and validate drug targets. Researchers are investigating RNAi-based compounds as novel therapeutics to treat a variety of human diseases that are currently lacking sufficient treatment. To date, numerous studies support that RNAi therapeutics can improve disease phenotypes in various rodent models of human disease. Here, we focus on the development of RNAi-based therapies aimed at treating neurological disorders for which reduction of mutant or toxic gene expression may provide clinical benefit. We review RNAi-based gene-silencing strategies, proof-of-concept studies testing therapeutic RNAi for CNS disorders, and highlight the most recent research aimed at transitioning RNAi-based therapeutics toward clinical trials. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:112 / 121
页数:10
相关论文
共 50 条
  • [41] Delivering RNAi therapeutics: From discovery to applications
    Manoharan, Muthiah
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [42] Delivery of RNAi Therapeutics to the AirwaysFrom Bench to Bedside
    Qiu, Yingshan
    Lam, Jenny K. W.
    Leung, Susan W. S.
    Liang, Wanling
    MOLECULES, 2016, 21 (09):
  • [43] RNAi extravaganza: from biochemistry to drugs and therapeutics
    Appasani, Krishnarao
    PHARMACOGENOMICS, 2007, 8 (08) : 889 - 893
  • [44] RNAi therapeutics: How likely, how soon?
    Robinson, R
    PLOS BIOLOGY, 2004, 2 (01) : 18 - 20
  • [45] RNAi THERAPEUTICS: A TWO-YEAR UPDATE
    Perkel, Jeffrey M.
    SCIENCE, 2009, 326 (5951) : 454 - 456
  • [46] Advances in RNAi therapeutics: Chemistry, mechanism and applications
    Manoharan, Muthiah
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [47] PAMAM dendrimers as promising nanocarriers for RNAi therapeutics
    Kesharwani, Prashant
    Banerjee, Sanjeev
    Gupta, Umesh
    Amin, Mohd Cairul Iqbal Mohd
    Padhye, Subhash
    Sarkar, Fazlul H.
    Iyer, Arun K.
    MATERIALS TODAY, 2015, 18 (10) : 565 - 572
  • [48] Advances and hurdles to clinical translation of RNAi therapeutics
    Kwon, Ick Chan
    Kataoka, Kazunori
    ADVANCED DRUG DELIVERY REVIEWS, 2016, 104 : 1 - 1
  • [49] RNAi therapeutics: an antiviral strategy for human infections
    Kelleher, Anthony D.
    Cortez-Jugo, Christina
    Cavalieri, Francesca
    Qu, Yijiao
    Glanville, Allan R.
    Caruso, Frank
    Symonds, Geoff
    Ahlenstiel, Chantelle L.
    CURRENT OPINION IN PHARMACOLOGY, 2020, 54 : 121 - 129
  • [50] Targeted delivery of RNAi therapeutics for cancer therapy
    Li, Jun
    Huang, Leaf
    NANOMEDICINE, 2010, 5 (10) : 1483 - 1486